In a new multicenter study, scientists demonstrate that a high-speed COVID-19 test has 94 per cent sensitivity and 100 per cent specificity. The test can be performed at a patient’s bedside and is currently being used successfully across eight London Hospitals.
In this Research Article, published by Bioanalysis, investigators from Case Western Reserve University (OH, USA) investigate whether different preanalytical blood processing techniques influence results of digital enzyme-linked immunosorbent assay (ELISA)-based assays for blood biomarkers.
This ‘In the Zone’ discusses the importance of data management. Data management is a common term used in almost all industries and it comprises all disciplines related to managing data as a valuable resource.
Researchers from the University of Leeds (UK) have described a new biosensing platform for detecting biomarkers that makes use of ‘DNA origami’ – folding of DNA molecules into specific nanostructures – and nanopores to enable individual biomarker detection.
Researchers from the University of Illinois at Urbana–Champaign (IL, USA) have demonstrated a prototype of a rapid, portable SARS-CoV-2 detection system that does not require an RNA extraction kit, thereby ‘bypassing the lab’. If approved, such a device could enable point-of-care COVID-19 diagnosis.
Approaches to improve drug tolerance and target tolerance in the assessment of neutralizing anti-drug antibodies
In this research article, published by Bioanalysis, investigators from Janssen Research & Development LLC and Thomas Jefferson University (both PA, USA) describe potential approaches for enabling the development of reliable neutralizing anti-drug antibody (NAb) assays that overcome drug and drug target interference for more precise and sensitive NAb assessment.
BioAgilytix (NC, USA) and BRIO Systems (MA, USA) have launched COVIDenceTM, their complete COVID-19 workforce testing service for employers.
Researchers from The University of Texas (TX, USA) have explained two different types of detectable antibody responses to the SARS-CoV-2 virus that may indicate different outcomes in terms of protection against reinfection of COVID-19.
Researchers from the University of Birmingham (Birmingham, UK) and Newcastle University (Newcastle, UK) have investigated a key enzyme utilized by gut bacteria that could be developed as a biomarker for intestinal diseases.
At a time where the world is looking to repurposed drugs to give the quickest treatment option to the COVID-19 pandemic, we interview David Fajgenbaum (University of Pennsylvania (PA, USA) and bestselling author of ‘Chasing My Cure’) on what type of treatment he considers to hold the most promise.